descript
purpos
aga
institut
clinic
practic
updat
rapidli
review
emerg
evid
provid
time
expert
recommend
regard
manag
patient
inflammatori
bowel
diseas
pandem
method
expert
commentari
commiss
approv
aga
institut
clinic
practic
updat
committe
cpuc
aga
govern
board
provid
time
perspect
topic
high
clinic
import
aga
membership
underw
intern
peer
review
cpuc
extern
peer
review
standard
procedur
gastroenterolog
decemb
numer
peopl
citi
wuhan
hubei
provinc
china
develop
infect
respiratori
symptom
unknown
pathogen
within
month
scientist
identifi
novel
coronaviru
name
viru
design
intern
committe
taxonomi
virus
world
health
organ
subsequ
name
diseas
produc
covid
shortli
thereaft
rapidli
spread
wuhan
februari
confirm
case
death
china
countri
time
quarantin
method
contain
start
viru
alreadi
spread
worldwid
march
world
health
organ
declar
pandem
april
confirm
case
death
affect
age
group
children
older
adult
men
women
wors
outcom
patient
comorbid
chronic
ill
respiratori
ill
diabet
obes
hypertens
rna
viru
similar
prior
coronavirus
known
presum
enter
human
popul
anim
respiratori
manifest
similar
two
prior
coronaviru
outbreak
sever
acut
respiratori
syndrom
sarscov
middl
eastern
respiratori
syndrom
merscov
thought
transmit
via
droplet
possibl
airborn
inhal
aerosol
particl
droplet
transmiss
occur
typic
close
contact
person
cough
sneez
respiratori
droplet
come
contact
mucos
membran
mouth
nose
conjunctiva
eye
addit
transmiss
occur
contact
surfac
contamin
respiratori
droplet
airborn
transmiss
occur
virion
within
droplet
nuclei
gener
particl
diamet
remain
air
long
period
time
transmit
other
distanc
greater
airborn
transmiss
like
major
mode
transmiss
commun
definit
concern
clinic
situat
aerosol
gener
endotrach
intub
nasopharyng
suction
endoscop
procedur
addit
detect
stool
postul
fecal
transmiss
may
possibl
confirm
recent
report
confirm
detect
viral
particl
stool
suggest
quantiti
infecti
enter
cell
via
angiotensinconvert
enzym
receptor
spike
protein
viru
prime
transmembran
proteas
serin
precursor
facilit
viruscel
membran
fusion
receptor
express
differ
cell
type
bodi
appear
express
intestin
found
mani
organ
includ
lung
tongu
pancrea
common
symptom
fever
respiratori
symptom
understood
signific
proport
patient
alter
bowel
habit
digest
symptom
symptom
may
reflect
inocul
gastrointestin
gi
tract
swallow
viru
due
express
intestin
addit
recent
report
focus
girel
manifest
well
fact
viru
detect
stool
long
resolut
respiratori
symptom
even
detect
viru
oropharynx
pandem
global
health
emerg
patient
inflammatori
bowel
diseas
ibd
particular
concern
risk
infect
manag
medic
therapi
clinic
practic
updat
incorpor
emerg
understand
summar
avail
guidanc
patient
ibd
provid
take
care
expert
commentari
commiss
approv
aga
institut
clinic
practic
updat
committe
cpuc
aga
govern
board
provid
time
perspect
topic
high
clinic
import
aga
membership
underw
intern
peer
review
cpuc
extern
peer
review
standard
procedur
gastroenterolog
number
key
question
immedi
come
mind
patient
inflammatori
bowel
diseas
ibd
contact
well
scientif
commun
whole
highlight
tabl
address
updat
reader
advis
understand
novel
coronaviru
progress
ibdspecif
issu
recommend
may
chang
well
understand
patient
crohn
diseas
cd
ulcer
coliti
uc
specif
concern
potenti
increas
risk
infect
control
chronic
inflamm
often
involv
use
immunosuppress
immun
modifi
therapi
welldescrib
risk
viral
infect
addit
need
medic
facil
may
increas
risk
exposur
due
receiv
infus
infus
center
endoscop
procedur
despit
potenti
increas
exposur
limit
avail
data
expert
opinion
suggest
patient
ibd
appear
baselin
increas
risk
infect
develop
unclear
whether
inflamm
bowel
per
se
risk
infect
sensibl
patient
ibd
maintain
remiss
order
reduc
risk
relaps
need
intens
medic
therapi
hospit
limit
inform
document
bowel
inflamm
routin
assess
patient
howev
establish
viral
rna
identifi
roughli
half
patient
persist
mani
even
respiratori
sampl
turn
neg
clear
associ
gi
symptom
presenc
viral
rna
stool
diarrhea
patientdefin
present
hospit
patient
wuhan
china
icu
anoth
studi
show
roughli
half
patient
digest
symptom
part
present
hospit
pneumonia
one
third
diarrhea
interest
patient
gi
symptom
zhejiang
provinc
much
lower
incid
gi
symptom
reflect
possibl
differ
viral
strain
report
differ
report
patient
digest
symptom
frequent
concurr
fever
respiratori
symptom
well
given
preval
nonspecif
digest
symptom
popul
especi
patient
ibd
clinic
implic
quit
import
patient
develop
new
digest
symptom
fever
respiratori
symptom
monitor
progress
symptom
might
guid
time
test
patient
ibd
trigger
addit
treatment
adjust
limit
data
china
europ
outcom
patient
ibd
develop
intern
registri
secureibd
establish
collect
inform
patient
ibd
confirm
test
posit
earli
make
definit
conclus
patient
report
registri
time
write
patient
sever
ibd
report
physician
global
assess
like
hospit
relat
ibd
anticip
robust
data
upcom
one
two
month
case
worldwid
grow
establish
case
report
covidibdorg
common
question
pose
patient
ibd
provid
one
ibd
therapi
patient
current
pandem
especi
suspect
confirm
absenc
outcom
data
must
reli
upon
inform
date
well
expert
guidanc
challeng
time
end
incorpor
gener
guidanc
consensu
statement
british
societi
gastroenterolog
bsg
intern
organ
studi
inflammatori
bowel
diseas
ioibd
divid
consider
therapi
manag
ibd
three
categori
patient
ibd
infect
patient
ibd
infect
asymptomat
eg
ibd
remiss
develop
manifest
patient
ibd
confirm
without
activ
bowel
inflamm
digest
symptom
avail
data
expert
opinion
suggest
patient
ibd
higher
risk
infect
therefor
gener
recommend
stay
ibd
therapi
goal
sustain
remiss
ideal
defin
composit
symptomat
clinic
remiss
object
confirm
inflamm
control
endoscop
improv
normal
laboratori
valu
patient
advis
maintain
current
regimen
avoid
relaps
due
nonadher
asid
obviou
neg
consequ
relaps
relaps
ibd
strain
avail
medic
resourc
may
requir
steroid
therapi
necessit
hospit
outcom
much
wors
known
risk
exist
ibd
therapi
similar
recommend
gener
popul
patient
ibd
practic
strict
social
distanc
work
home
meticul
hand
hygien
separ
known
infect
individu
wuhan
ibd
center
experi
patient
demonstr
benefit
approach
healthcar
team
institut
immedi
alert
popul
stay
home
practic
strict
social
distanc
despit
epicent
wuhan
none
patient
subsequ
develop
patient
ibd
provid
express
concern
go
infus
center
deliveri
infus
ibd
therapi
eg
infliximab
ustekinumab
vedolizumab
ioibd
consensu
support
ongo
use
infus
center
provid
center
screen
protocol
place
infus
center
protocol
includ
prescreen
patient
exposur
symptom
fever
check
door
adequ
space
chair
minimum
feet
mask
glove
use
provid
provid
patient
adequ
deep
clean
patient
departur
elect
switch
inject
therapi
recommend
prior
trial
explor
patient
receiv
infliximab
switch
adalimumab
associ
relaps
addit
switch
home
infus
may
seem
appeal
way
limit
exposur
recommend
mani
uncontrol
variabl
seriou
risk
nurseprovid
travel
home
home
may
becom
infect
act
vector
patient
test
becom
widespread
pointofcar
test
use
sensit
nucleic
acid
detect
serolog
antibodi
develop
addit
discuss
test
patient
prior
endoscop
procedur
surgeri
even
specif
symptom
suggest
therefor
situat
patient
known
infect
viru
diseas
possibl
increas
ioibd
specif
explor
scenario
develop
guidanc
statement
scenario
patient
activ
move
lower
dose
prednison
mgd
transit
budesonid
feasibl
thiopurin
methotrex
tofacitinib
temporarili
held
avail
monoclon
antibodi
therapi
antitumor
necrosi
factor
tnf
therapi
ustekinumab
vedolizumab
dose
delay
week
monitor
develop
gener
consider
readili
acknowledg
halfliv
therapi
medic
may
continu
system
tissu
effect
despit
discontinu
restart
therapi
week
patient
develop
manifest
reason
like
soon
abl
perform
serial
test
look
disappear
igm
develop
igg
antibodi
order
know
phase
infect
patient
enter
provid
precis
comfort
regard
time
restart
therapi
held
given
persist
stool
longer
detect
nasopharyng
swab
known
whether
prefer
test
howev
practic
point
view
serial
stool
test
like
adopt
therefor
clinic
signific
stool
test
set
remain
seen
third
scenario
challeng
implic
manag
ibd
well
manag
bsg
ioibd
statement
address
approach
manag
ibd
medic
scenario
detail
assess
state
ibd
complex
develop
gener
algorithm
approach
figur
patient
adjust
medic
therapi
ibd
appropri
base
understand
immun
activ
therapi
whether
therapi
may
worsen
outcom
first
consid
patient
whose
ibd
remiss
adjust
ibd
therapi
focus
reduc
immun
suppress
activ
viral
replic
attempt
reduc
likelihood
complic
known
anticytokinebas
treatment
studi
therapi
possibl
learn
exampl
continu
antitnf
therapi
might
reduc
progress
acut
respiratori
distress
syndrom
multiorgan
system
failur
howev
absenc
data
guidanc
current
base
decid
whether
hold
continu
specif
ibd
therapi
addit
interest
antivir
therapi
anticytokin
therapi
studi
choos
therapi
may
secondari
benefit
ibd
least
induc
bowel
inflamm
would
appropri
consid
interest
research
potenti
medic
therapi
treat
patient
particular
attent
therapi
use
primarili
rheumatoid
arthriti
blocker
tocilizumab
use
rheumatoid
arthriti
giantcel
arter
agent
also
proven
efficaci
fda
approv
treatment
cytokinereleas
syndrom
condit
becom
common
era
chimer
antigen
receptor
tcell
cart
cancer
therapi
tocilizumab
posit
phase
data
publish
cd
activ
studi
patient
anoth
antiil
agent
sarilumab
separ
janu
kina
inhibitor
baracitinib
tofacitinib
may
interfer
viru
enter
cell
inhibit
protein
mediat
endocytosi
addit
hydroxychloroquin
receiv
intern
attent
possibl
therapeut
agent
patient
one
older
medic
use
ibd
albeit
uncontrol
fashion
reader
encourag
get
latest
updat
antiinflammatori
therapi
http
clinicaltrialsgov
regard
ibd
therapi
aminosalicyl
topic
rectal
therapi
dietari
manag
antibiot
consid
safe
may
continu
oral
budesonid
like
safe
well
continu
need
ongo
control
ibd
system
corticosteroid
avoid
discontinu
quickli
possibl
appropri
caution
concern
adren
insuffici
chronic
corticosteroid
use
thiopurin
methotrex
tofacitinib
discontinu
acut
ill
antitnf
therapi
ustekinumab
also
held
viral
ill
ioibd
group
uncertain
hold
vedolizumab
necessari
situat
patient
whose
ibd
stabl
hold
time
viral
ill
appropri
patient
digest
symptom
ongo
support
care
primari
reason
investig
caus
digest
symptom
ibd
patient
critic
import
first
exclud
known
enter
infect
clostridioid
difficil
gi
pathogen
second
confirm
activ
inflamm
nonendoscop
approach
includ
creactiv
protein
fecal
calprotectin
crosssect
imag
although
test
interpret
caution
may
abnorm
due
result
suggest
relaps
ibd
treatment
ibd
base
activ
inflamm
sever
ibd
mildli
activ
diseas
clinician
util
safer
therapi
mention
moder
sever
activ
diseas
hold
therapi
may
safe
practic
set
risk
benefit
escal
ibd
therapi
must
care
weigh
sever
outpati
mild
symptom
ioibd
support
use
usual
treatment
would
consid
hospit
patient
sever
risk
poor
outcom
ibd
therapi
like
take
back
seat
choic
therapi
take
account
coexist
ibd
feasibl
interest
clearanc
cmv
enhanc
ibd
therapi
ad
ganciclovir
thiopurin
cyclosporin
may
anticoronaviru
properti
patient
hospit
ibd
also
milder
incident
identifi
focu
address
sever
acut
issu
ibd
import
standard
algorithm
appli
care
hospit
patient
ibd
follow
given
evid
poor
outcom
sar
rsv
patient
treat
highdos
corticosteroid
well
intrigu
data
possibl
role
cyclosporin
tacrolimu
therapi
interfer
sarscov
viral
replic
suggest
limit
iv
steroid
three
day
point
decis
proceed
calcineurin
inhibitor
infliximab
made
urgent
endoscop
procedur
may
chang
direct
therapi
remain
indic
pandem
cmv
test
may
done
serum
pcr
avoid
need
colonoscop
procedur
ganciclovir
start
quantit
suggest
activ
inflamm
surgic
consult
advis
per
standard
clinic
practic
although
desir
minim
surgic
intervent
pandem
put
emphasi
find
effect
medic
stopgap
patient
howev
clearli
patient
despit
medic
intervent
still
requir
surgeri
takehom
point
tabl
risk
patient
ibd
